Načítá se...
PD-L1 mAb Treats Ischemic Stroke by Controlling CNS Inflammation
BACKGROUND AND PURPOSE: Both pathogenic and regulatory immune processes are involved in the middle cerebral artery occlusion (MCAO) model of experimental stroke, including interactions involving the Programmed Death 1 (PD-1) receptor and its two ligands, PD-L1 and PD-L2. Although PD-1 reduced stroke...
Uloženo v:
| Vydáno v: | Stroke |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4589506/ https://ncbi.nlm.nih.gov/pubmed/26306753 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/STROKEAHA.115.010592 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|